louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01725893: Percutaneous Tenotomy of the Toe Flexor Tendon is a Simple and Efficient Method in Treating Checkrein Deformity
Official title: Percutaneous Tenotomy of the Toe Flexor Tendon is a Simple and Efficient Method in Treating Checkrein Deformity
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Claw Toe
Keywords: Claw Toe
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2012-11-14
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 73
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: There were fourteen patients with checkrein deformity who underwent surgery in our hospital between 1993 and 2010.

Brief summary: Checkrein deformity represents a dynamic claw toe deformity. Surgical intervention is the treatment of choice and many methods have been proposed. The purpose of this study is to evaluate the outcomes and complications of percutaneous segmental tenotomy of the toe flexor tendons.

Detailed description: The investigators reviewed fourteen patients with checkrein deformity who underwent surgery in our hospital between 1993 and 2010. Five patients received FHL and flexor digitorum longus (FDL) tenolysis at the musculotendinous junction; among them, two also underwent Z-plasty lengthening of the FHL tendon. Nine patients underwent percutaneous segmental toe flexor tenotomy. The Hallux Metatarsophalangeal- Interphalangeal Scale (Hallux MTP-IP scale) and Foot and Ankle Outcome Score (FAOS), English version LK1.0 self-explanatory questionnaire were used to evaluate the functional outcomes.

Eligibility criteria: Inclusion Criteria:

* Patients with checkrein deformity who underwent surgery in our hospital between 1993 and 2010.

Exclusion Criteria:

* Patients who had static or rigid claw toe deformity
* Patients who had claw toe deformity secondary to neuromuscular disease

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital (NTUH) Research Ethics Committee (REC)
name: Hong-Nerng Ho, Professor
role: STUDY_CHAIR
References:
citation: Lee HS, Kim JS, Park SS, Lee DH, Park JM, Wapner KL. Treatment of checkrein deformity of the hallux. J Bone Joint Surg Br. 2008 Aug;90(8):1055-8. doi: 10.1302/0301-620X.90B8.20563.
Clinical trial NCT04931693: PECs Block for Pacemaker Insertion in Children
Official title: Evaluation of Ultrasound Guided Modified Pectoral Nerves Blocks in Transvenous Subpectoral Pacemaker Insertion in Children: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Complete Heart Block
Lead sponsor: Kasr El Aini Hospital
Sponsor class: OTHER
First posted: 2021-06-18
Enrollment: 40
Sex: ALL
Minimum age (years): 1
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The patient will be randomly assigned to two equal groups. conventional control group(C) (n=20) where20 children will receive IV paracetamol 20 mg / kg . and Pectoral nerves blocks group (P) (n=20) where 20 children will have PECs Block .
Primary purpose: TREATMENT

Brief summary: Evaluation of Ultrasound Guided Modified Pectoral Nerves Blocks in Transvenous Subpectoral pacemaker insertion in Children: Randomized Controlled Trial

Detailed description: BACKGROUND Pectoral nerve blocks (PECs) can reduce intraprocedural anesthetic requirements and postoperative pain. Little is known about the utility of PECs in reducing pain and narcotic use after pacemaker (PM)placement in children. OBJECTIVE The purpose of this study was to determine whether PECs can decrease postoperative pain and opioid use after PM placement in children.

METHODS A single-center controlled trial of pediatric patients undergoing transvenous PM placement between 2020 and 2021 will be performed. Demographics, procedural variables, postoperative pain, and postoperative opioid usage will be compared between patients who undergone PECs and those who undergone conventional anesthetic (Control).

Eligibility criteria: Inclusion Criteria:

* congenital or post-operative heart block.

Exclusion Criteria:

* ⦁ Redo patient

  * History of allergic reactions to local anesthetics.
  * Bleeding disorders with International Normalization Ratio( INR) \> 1.5 and/or platelets \< 50 000.
  * Rash or signs of infection at the injection site.
  * Emergency procedure

Primary outcomes:
measure: Mean Post-operative pain score by The Face, Legs, Activity, Cry, Consolability scale (FLACC) scale.
timeFrame: immediate, 6,12 ,18 and 24 hours after intervention
Secondary outcomes:
measure: Total consumption of opioids.
timeFrame: immediate, 6,12 ,18 and 24 hours after intervention
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr Al Ainy Hospital
Study officials:
References:
citation: Anderson R, Harukuni I, Sera V. Anesthetic considerations for electrophysiologic procedures. Anesthesiol Clin. 2013 Jun;31(2):479-89. doi: 10.1016/j.anclin.2013.01.005. Epub 2013 Feb 23.
citation: Yang JK, Char DS, Motonaga KS, Navaratnam M, Dubin AM, Trela A, Hanisch DG, McFadyen G, Chubb H, Goodyer WR, Ceresnak SR. Pectoral nerve blocks decrease postoperative pain and opioid use after pacemaker or implantable cardioverter-defibrillator placement in children. Heart Rhythm. 2020 Aug;17(8):1346-1353. doi: 10.1016/j.hrthm.2020.03.009. Epub 2020 Mar 20.
Clinical trial NCT01211093: Acute Effects of Whole Body Vibration in Chronic Stroke
Official title: The Acute Effects of Whole Body Vibration Training With Different Frequencies on Neuromotor Performance in Individuals With Stroke
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Stroke
Keywords: vibration
muscle
cerebrovascular accident
exercise
rehabilitation
Lead sponsor: The Hong Kong Polytechnic University
Sponsor class: OTHER
First posted: 2010-09-29
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Whole body vibration has been found to be useful in promoting bone health, balance, and muscle performance in older adults. The overall aim of the proposed study is to determine whether whole body vibration (WBV) has immediate beneficial effect in neuromotor performance in patients with stroke. It is hypothesized that a single session of WBV will induce significant improvement in leg muscle strength in people with chronic stroke.


Eligibility criteria: Inclusion Criteria:

* a diagnosis of stroke
* stroke onset \>6 months
* \>18 years of age
* \>able to walk for short distance independently with or without walking aid
* able to understand simple verbal commands

Exclusion Criteria:

* other neurological conditions
* peripheral vascular disease
* vestibular disorders
* significant musculoskeletal disorders (e.g. rheumatoid arthritis)
* pregnancy

Primary outcomes:
measure: knee extension isokinetic strength
timeFrame: 2 weeks
Secondary outcomes:
measure: Muscle activity (electromyography) of knee extensors
timeFrame: during treatment
measure: knee extension isometric strength
timeFrame: 2 weeks
measure: knee flexion isometric strength
timeFrame: 2 weeks
measure: knee flexion isokinetic strength
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: The Hong Kong Polytechnic University
Study officials:
affiliation: The Hong Kong Polytechnic University
name: Marco YC Pang, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00284193: Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII
Official title: Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hemophilia A
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2006-01-31
Enrollment: 5
Sex: MALE
Minimum age (years): 16
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients with severe hemophilia and inhibitors can be treated effectively by Activated Prothrombin Complex Concentrates (APCC, eg. FEIBA) or High dose recombinant factor VIIa (rFVIIa). Rarely, such patients develop refractoriness to these products for whom therapy with sequential FEIBA and rFVIIa has been recently suggested.

The impetus for the present report was a hemophilia A patient with high titer inhibitor (1300BU) who had life threatening hematuria that was resistant to repeated doses of 400µg/kg rFVIIa up to a cumulative dose of 1200 µg/kg given over 6-9 hours.

Thrombin generation (TG) tested in vitro was consistent with resistance to high concentrations of rFVIIa but yielded good response to combinations of low doses of rFVIIa+FEIBA. In a desperate attempt to control the bleeding, concomitant therapy of 25 U/kg FEIBA and 40µg/kg rFVIIa was infused and resulted in arrest of bleeding within minutes. Over a span of about one year the patient has been successfully treated by this combination for more than 200 bleeding episodes in muscles and joints.

Detailed description: Inhibitor patients with HR inhibitors were eligible for study enrollment. After consent blood was drawn and ex- vivo spiked with rFVIIa/FEIBA and combinations, assayed by thrombin generation tests.

The combination yielding sufficient hemostasis was depicted for patients' therapy of future bleeding episodes.

Following actual therapy hemostasis and safety parameters were monitored.

Eligibility criteria: Inclusion Criteria:

* Hemophilia patients with inhibitors
* Patients signing informed consent

Exclusion Criteria:

* Patients under 16 or above 65
* Patients with allergic reaction or adverse events in previous use the concentrates
* Patients with high risk of thrombosis

Primary outcomes:
measure: Hemostasis achieved post therapy
timeFrame: 6-24 hours
measure: Safety
timeFrame: 0-24 HOURS
Secondary outcomes:
measure: Time to Hemostasis
timeFrame: 0-24 HOURS
Other outcomes:
measure: Coagulation Studies
timeFrame: 0-24 HOURS
Locations:
Study officials:
affiliation: Sheba Medical Center
name: Uri Martinowitz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03535493: The Effect of ACT and Float REST on Burnout Syndrome.
Official title: The Effect of Acceptance and Commitment Therapy (ACT) and Float REST (Restricted Environmental Stimulation Therapy) on Burnout Syndrome.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Burnout Syndrome
Lead sponsor: International Behavioral Research Institute
Sponsor class: OTHER
First posted: 2018-05-24
Enrollment: 45
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: In 1982, Steven Hayes, a clinical psychologist, developed Acceptance and Commitment Therapy (ACT), a unique empirically based psychological intervention that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies, to increase psychological flexibility. In 1954, John Lilly, a cognitive neuroscientist, developed the sensory deprivation tank (known today as Floatation Restricted Environmental Stimulation Therapy - Float REST), to access a wide range of healing, higher brain functions, and meditation through an unparalleled deep relaxation state. In this study, the investigators aim to examine whether participants in the ACT + Float REST condition will have larger decreases of the burnout phenomenon than those who receive either only ACT or Float REST.



Primary outcomes:
measure: Assessing Change in Maslach Burnout Inventory - Human Services Survey (MBI-HSS)
timeFrame: Metric will be used as screening prior to study intervention; continuous measurement at week 2, week 4, week 6, week 8 and at one month follow-up.
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Charles
country: United States
facility: International Behavioral Research Institute
state: Illinois
Study officials:
References:
Clinical trial NCT01838993: Inhalation of Lidocaine Before Intubation
Official title: The Effect of Ultrasonic Nebulizer Delivered Lidocaine on Circulatory Responses During Tracheal Intubation and Postoperative Sore Throat
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sore Throat
Keywords: anesthetics,
local,
lidocaine;
nebulizers and vaporizers;
complications,
intubation,
intratracheal.
Lead sponsor: New Taipei City Hospital
Sponsor class: OTHER
First posted: 2013-04-24
Enrollment: 70
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: We investigate the potential benefits of ultrasound-driven lidocaine inhalation immediately before induction.

Detailed description: Sudden increases in blood pressure and heart rate after tracheal intubation and post-operative sore throat are two common undesirable side effects of general anesthesia and might lead to patients' morbidity or dissatisfaction. We investigated the possibility to attenuate both side effects with one single method, i.e. ultrasound-driven lidocaine inhalation immediately before induction.

Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status I or II. Patients scheduled for elective surgery under general anesthesia with orotracheal intubation

Exclusion Criteria:

* patient's refusal to join, major surgery or expected operation duration longer than 3 hours, patients with a anticipated difficult airway, requiring a nasogastric tube in peri-operative stage, having recent upper respiratory tract infection (within 1 week) or pre-existing sore throat.

Primary outcomes:
measure: Blood pressure
timeFrame: 3 min
Secondary outcomes:
measure: Post operative sore throat
timeFrame: 3 days
Other outcomes:
Locations:
city: New Taipei City
country: Taiwan
facility: New Taipei City Hospital
Study officials:
affiliation: New Taipei City Hospital
name: Chen Yen Po, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00557011: NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD
Official title: A Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled, 3-Treatment, 3-Period, Crossover Study With One Week Per Treatment and Once-a-Day Dosing of Either NRP104, Adderall XR, or Placebo in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Attention Deficit Disorder With Hyperactivity
Lead sponsor: New River Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2007-11-12
Enrollment: 52
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess, in a controlled environment, the efficacy and safety of NRP104 and Adderall XR compared to placebo in treatment of children, aged 6-12, with ADHD.


Eligibility criteria: Inclusion Criteria:

* males and non-pregnant females, aged 6-12 years DSM-IV-TR criteria for diagnosis of ADHD, combined or hyperactive-impulsive subtypes
* on stable regimen of stimulants for at least one month in the last six months and has shown adequate response to stimulants without unacceptable side effects

Exclusion Criteria:

* co-morbid psychiatric diagnosis such as psychosis, bipolar illness, severe OCD, severe depressive or anxiety disorder
* history of seizure during the last 2 years, a tic disorder or Tourette's
* clinically significant ECG or laboratory abnormalities at screening or baseline
* taking clonidine or anticonvulsant drugs
* taking medications that affect blood pressure or heart rate

Primary outcomes:
measure: SKAMP-DS scores across a treatment assessment day
timeFrame: 1 week
Secondary outcomes:
measure: SKAMP Attention Scale, PERMP attempted score, PERMP correct score, and CGI scores across the treatment assessment day
timeFrame: 1 week
measure: Treatment emergent adverse events
timeFrame: 1 week
measure: PK profile and PK/PD relationship of NRP104
timeFrame: After multiple doses
Other outcomes:
Locations:
Study officials:
affiliation: Harvard Medical School (HMS and HSDM)
name: Joseph Biederman, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Clinical Study Centers, LLC
name: Samuel Boellner, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Center for Psychiatry And Behavioral Medicine Inc.
name: Ann Childress, M.D.
role: PRINCIPAL_INVESTIGATOR
name: Frank Lopez, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007 Nov 1;62(9):970-6. doi: 10.1016/j.biopsych.2007.04.015. Epub 2007 Jul 12.
citation: Faraone SV, Spencer TJ, Kollins SH, Glatt SJ. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. J Am Acad Child Adolesc Psychiatry. 2010 Jan;49(1):24-32. doi: 10.1097/00004583-201001000-00006.
Clinical trial NCT00728611: Preparation Rich in Growth Factors (PRGF) Treatment for Osteoarthritis of the Knee
Official title: PRP as a Treatment for Knee Osteoarthritis - Randomized-double-blind-placebo Control Trail.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Osteoarthritis of the Knee
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2008-08-06
Enrollment: 60
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: to evaluate the influence of PRGF treatment on patient suffering from OA knee

Detailed description: Autologous platelet-secreted growth factors (GFs) may have therapeutic effects in osteoarthritis (OA) capsular joints via multiple mechanisms. Our aim is to examine the effect of a platelet-derived preparation rich in growth factors (PRGFs) in OA knee

Eligibility criteria: Inclusion Criteria:

* age 40-75 years old
* diagnosed Oa of the knee more then 1 year
* no knee deformation

Exclusion Criteria:

* mental of physical disabilities
* pregnancy
* deformities of the knee

Primary outcomes:
measure: Improvment of symptomes
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Kfar Saba
country: Israel
facility: Meir Medical Center
Study officials:
References:
Clinical trial NCT01617811: Effect of Epidural Anesthesia and Analgesia on Patients' Outcomes After Liver Resection
Official title: Effects of Epidural Anesthesia and Analgesia on Postoperative Metabolic, Immune Function and Hemodynamic Changes of Open Liver Resection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatectomy
Lead sponsor: Sir Run Run Shaw Hospital
Sponsor class: OTHER
First posted: 2012-06-12
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to analyze the effects of epidural anesthesia and analgesia on intraoperative clinical outcome, postoperative recovery, metabolic changes, and immune functions of the patients receiving open liver resection.


Eligibility criteria: Inclusion Criteria:

* left hemihepatectomy left lateral sectionectomy clinical diagnosis of hepatolithiasis

Exclusion Criteria:

* abnormal coagulation tests diabetes mellitus significant cirrhosis

Primary outcomes:
measure: Clinical outcomes during and after open liver resection
timeFrame: participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary outcomes:
measure: Cytokine change in perioperation of open liver resection
timeFrame: Before operation, within 5 days after operation
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
state: Zhejiang
Study officials:
References:
Clinical trial NCT02607111: A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients
Official title: A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients: A Prospective Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Kidney Failure
Keywords: Dalteparin
Dosage
Home Hemodialysis
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
First posted: 2015-11-17
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study evaluates the optimal dosage and safety of Dalteparin when used as an anticoagulant for hemodialysis therapies.

Detailed description: Routine anticoagulation is required during hemodialysis treatments. In North America, the anticoagulant of choice for hemodialysis therapies is unfractionated heparin (UFH), whereas in Western Europe, it is low molecular weight heparin (LMWH). Dalteparin is more commonly used in Canada and has been approved for use in the in-centre thrice-weekly hemodialysis population at a fixed dose of 5000 units. However, there have been no published studies to assess the use of dalteparin in home quotidian and/or nocturnal hemodialysis therapies. Patients on frequent hemodialysis or nocturnal hemodialysis in the home will be converted to Dalteparin from Heparin for 4 weeks to evaluate the optimal dosage and to assess its safety in this population

Eligibility criteria: Inclusion Criteria:

* Currently undergoing short-hour daily and nocturnal hemodialysis through the home dialysis program at London Health Sciences Centre.

Exclusion Criteria:

* Patients with increased bleeding risks
* Currently on full dose anticoagulants
* Active bleeding
* Diabetic retinopathy
* Active cancer receiving treatment within the past 6 months

Primary outcomes:
measure: The mean dalteparin dose for the daily home hemodialysis patients
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: Canada
facility: London Health Sciences Centre
state: Ontario
Study officials:
affiliation: London Health Sciences Centre
name: Susan Huang, MD
role: PRINCIPAL_INVESTIGATOR
References: